Using Molecular Stratification for Smart Combination Therapies

Amy B Hont¹, Catherine M Bollard¹

Affiliations

PMID: 34559549
DOI: 10.1200/JCO.21.01804

Editorial

Using Molecular Stratification for Smart Combination Therapies

Amy B Hont et al. J Clin Oncol. 2021.

. 2021 Nov 10;39(32):3527-3530.

doi: 10.1200/JCO.21.01804. Epub 2021 Sep 24.

Authors

Amy B Hont¹, Catherine M Bollard¹

Affiliation

¹ Center for Cancer and Immunology Research, Children's National Hospital and The George Washington University, Washington, DC.

PMID: 34559549
DOI: 10.1200/JCO.21.01804

No abstract available

PubMed Disclaimer

Conflict of interest statement

Catherine M. BollardLeadership: Cabaletta BioConsulting or Advisory Role: Mana Therapeutics, Catamaran BioNo other potential conflicts of interest were reported.

Comment on

Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, Andre N, Aerts I, De Carli E, van Eijkelenburg N, Thebaud E, Corradini N, Defachelles AS, Ducassou S, Morscher RJ, Vassal G, Geoerger B. Bautista F, et al. J Clin Oncol. 2021 Nov 10;39(32):3546-3560. doi: 10.1200/JCO.21.01152. Epub 2021 Aug 4. J Clin Oncol. 2021. PMID: 34347542 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Using Molecular Stratification for Smart Combination Therapies

Affiliation

Using Molecular Stratification for Smart Combination Therapies

Authors

Affiliation

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources